ZBH
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Zimmer Biomet Holdings, Inc.
- Nom
- Zimmer Biomet Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $18.8B
- Employés
- 17,000
- PDG
- Ivan Tornos
- Site web
- https://www.zimmerbiomet.com
- Marché
- ALGNBSXEWGEHCMDTOFIX
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 8691 titres (~824028 USD)
- Insiders
- Phipps Chad FThornal Kevin R
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$824,028
Avg sell (VWAP, 90d window) $94.81 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-11
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Thornal Kevin R | Sell · S | 5,691 | $92.95 | $528,978 | Form 4 |
| 2026-09-04 | Phipps Chad F | Sell · S | 3,000 | $98.35 | $295,050 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-07-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-01-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-06-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-02-11 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-06-12 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-06-12 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-06-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-07 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-25 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-28 | Van Taylor | Sale (Full) | $100,001 - $250,000 |
| 2022-07-28 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2022-06-24 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-24 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-24 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-13 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-12-10 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2021-09-30 | Susie Lee | Sale (Full) | $15,001 - $50,000 |
| 2021-08-06 | Chuck Fleischmann | Sale (Full) | $1,001 - $15,000 |
| 2021-08-06 | Chuck Fleischmann | Sale (Full) | $1,001 - $15,000 |
| 2021-06-28 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-12-16 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-12-08 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-12-03 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-04-27 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2020-04-03 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-03-20 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2018-12-17 | David McKinley | Sale (Full) | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.98 · operating margin 17%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.6% | 71.5% | 71.8% | 70.9% | 71.3% | |
| Ebit Margin | 13.7% | 16.3% | 17.2% | 8.2% | 10.4% | |
| Ebitda Margin | 26.9% | 29.3% | 30.0% | 21.5% | 24.1% | |
| Operating Profit Margin | 16.5% | 16.7% | 17.3% | 10.0% | 12.6% | |
| Pretax Profit Margin | 10.1% | 13.5% | 14.4% | 5.8% | 7.3% | |
| Continuous Operations Profit Margin | 8.6% | 11.8% | 13.9% | 4.2% | 6.5% | |
| Net Profit Margin | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% | |
| Bottom Line Profit Margin | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% | |
| Current Ratio | 1.982 | 1.906 | 1.613 | 1.877 | 1.409 | |
| Quick Ratio | 1.097 | 0.994 | 0.778 | 0.967 | 0.789 | |
| Solvency Ratio | 0.173 | 0.214 | 0.219 | 0.128 | 0.124 | |
| Cash Ratio | 0.229 | 0.214 | 0.146 | 0.159 | 0.109 | |
| Price To Earnings Ratio | 25.258 | 23.737 | 24.786 | 115.909 | 63.855 | |
| Price To Earnings Growth Ratio | -1.263 | -2.534 | 0.072 | -2.695 | -0.165 | |
| Forward Price To Earnings Growth Ratio | -1.263 | -2.534 | 0.072 | -2.695 | -0.165 | |
| Price To Earnings Diluted Ratio | 25.330 | 23.844 | 24.939 | 115.909 | 64.524 | |
| Price To Earnings Diluted Growth Ratio | -1.275 | -2.586 | 0.073 | -2.733 | -0.168 | |
| Price To Book Ratio | 1.402 | 1.721 | 2.035 | 2.223 | 2.031 | |
| Price To Sales Ratio | 2.163 | 2.794 | 3.435 | 3.851 | 3.765 | |
| Price To Free Cash Flow Ratio | 12.090 | 18.776 | 21.396 | 25.044 | 19.082 | |
| Price To Operating Cash Flow Ratio | 10.491 | 14.308 | 16.059 | 20.802 | 17.148 | |
| Debt To Assets Ratio | 0.326 | 0.290 | 0.268 | 0.270 | 0.301 | |
| Debt To Equity Ratio | 0.592 | 0.498 | 0.462 | 0.474 | 0.558 | |
| Debt To Capital Ratio | 0.372 | 0.332 | 0.316 | 0.322 | 0.358 | |
| Long Term Debt To Capital Ratio | 0.353 | 0.300 | 0.281 | 0.300 | 0.301 | |
| Financial Leverage Ratio | 1.819 | 1.714 | 1.722 | 1.753 | 1.853 | |
| Working Capital Turnover Ratio | 3.461 | 3.866 | 3.870 | 3.981 | 3.463 | |
| Operating Cash Flow Ratio | 0.657 | 0.612 | 0.554 | 0.545 | 0.432 | |
| Operating Cash Flow Sales Ratio | 0.206 | 0.195 | 0.214 | 0.185 | 0.220 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.868 | 0.762 | 0.751 | 0.831 | 0.899 | |
| Debt Service Coverage Ratio | 2.377 | 1.961 | 1.978 | 1.950 | 0.878 | |
| Interest Coverage Ratio | 4.652 | 5.898 | 6.350 | 4.225 | 4.128 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.891 | 1.737 | 1.757 | 2.360 | 0.934 | |
| Operating Cash Flow Coverage Ratio | 0.226 | 0.242 | 0.274 | 0.226 | 0.212 | |
| Capital Expenditure Coverage Ratio | 7.559 | 4.202 | 4.009 | 5.904 | 9.863 | |
| Dividend Paid And Capex Coverage Ratio | 4.091 | 2.712 | 2.656 | 3.068 | 4.258 | |
| Dividend Payout Ratio | 0.270 | 0.217 | 0.196 | 0.869 | 0.498 | |
| Enterprise Value Multiple | 11.153 | 12.054 | 13.851 | 21.439 | 19.694 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.6% | ▼-9.8% | ▼-7.8% |
| Ebit Margin | 13.7% | ▼-2.7% | ▲0.5% |
| Ebitda Margin | 26.9% | ▼-2.4% | ▲0.6% |
| Operating Profit Margin | 16.6% | ▼-0.2% | ▲1.9% |
| Pretax Profit Margin | 10.1% | ▼-3.4% | ▼-0.1% |
| Continuous Operations Profit Margin | 8.6% | ▼-3.2% | ▼-0.4% |
| Net Profit Margin | 8.6% | ▼-3.2% | ▼-0.1% |
| Bottom Line Profit Margin | 8.6% | ▼-3.2% | ▼-0.1% |
| Current Ratio | 1.982 | ▲0.076 | ▲0.224 |
| Quick Ratio | 1.097 | ▲0.103 | ▲0.172 |
| Solvency Ratio | 0.173 | ▼-0.041 | ▲0.002 |
| Cash Ratio | 0.229 | ▲0.015 | ▲0.058 |
| Price To Earnings Ratio | 25.258 | ▲1.521 | ▼-25.451 |
| Price To Earnings Growth Ratio | -1.263 | ▲1.271 | ▲0.054 |
| Forward Price To Earnings Growth Ratio | -1.263 | ▲1.271 | ▲0.054 |
| Price To Earnings Diluted Ratio | 25.330 | ▲1.485 | ▼-25.579 |
| Price To Earnings Diluted Growth Ratio | -1.275 | ▲1.311 | ▲0.063 |
| Price To Book Ratio | 1.402 | ▼-0.319 | ▼-0.480 |
| Price To Sales Ratio | 2.163 | ▼-0.631 | ▼-1.039 |
| Price To Free Cash Flow Ratio | 12.090 | ▼-6.686 | ▼-7.187 |
| Price To Operating Cash Flow Ratio | 10.491 | ▼-3.817 | ▼-5.271 |
| Debt To Assets Ratio | 0.326 | ▲0.035 | ▲0.034 |
| Debt To Equity Ratio | 0.592 | ▲0.095 | ▲0.075 |
| Debt To Capital Ratio | 0.372 | ▲0.040 | ▲0.032 |
| Long Term Debt To Capital Ratio | 0.353 | ▲0.053 | ▲0.046 |
| Financial Leverage Ratio | 1.819 | ▲0.105 | ▲0.047 |
| Working Capital Turnover Ratio | 3.461 | ▼-0.405 | ▼-0.267 |
| Operating Cash Flow Ratio | 0.657 | ▲0.045 | ▲0.097 |
| Operating Cash Flow Sales Ratio | 0.206 | ▲0.011 | ▲0.002 |
| Free Cash Flow Operating Cash Flow Ratio | 0.868 | ▲0.106 | ▲0.046 |
| Debt Service Coverage Ratio | 2.377 | ▲0.416 | ▲0.549 |
| Interest Coverage Ratio | 4.652 | ▼-1.245 | ▼-0.398 |
| Short Term Operating Cash Flow Coverage Ratio | 2.891 | ▲1.153 | ▲0.955 |
| Operating Cash Flow Coverage Ratio | 0.226 | ▼-0.016 | ▼-0.010 |
| Capital Expenditure Coverage Ratio | 7.559 | ▲3.357 | ▲1.252 |
| Dividend Paid And Capex Coverage Ratio | 4.091 | ▲1.379 | ▲0.734 |
| Dividend Payout Ratio | 0.270 | ▲0.053 | ▼-0.140 |
| Enterprise Value Multiple | 11.153 | ▼-0.901 | ▼-4.485 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $17.80B | $21.45B | $25.40B | $26.72B | $25.71B | |
| Enterprise value | $24.73B | $27.13B | $30.75B | $32.04B | $32.40B | |
| EV / Sales | 3.00x | 3.53x | 4.16x | 4.62x | 4.75x | |
| EV / Op. cash flow | 14.57x | 18.10x | 19.44x | 24.94x | 21.61x | |
| EV / Free cash flow | 16.79x | 23.75x | 25.90x | 30.03x | 24.05x | |
| EV / EBITDA | 11.15x | 12.05x | 13.85x | 21.44x | 19.69x | |
| Net debt / EBITDA | 3.12x | 2.52x | 2.41x | 3.56x | 4.07x | |
| Current ratio | 1.98x | 1.91x | 1.61x | 1.88x | 1.41x | |
| Income quality | 2.41x | 1.66x | 1.54x | 4.41x | 3.37x | |
| Graham number | $72 | $78 | $81 | $38 | $51 | |
| Graham net-net | -$37 | -$30 | -$30 | -$31 | -$40 | |
| Tax burden | 84.9% | 87.2% | 95.9% | 57.3% | 80.5% | |
| Interest burden | 73.9% | 82.6% | 84.1% | 71.0% | 70.5% | |
| Working capital | $2.54B | $2.22B | $1.75B | $2.07B | $1.42B | |
| Invested capital | $19.41B | $17.82B | $17.49B | $17.59B | $17.71B | |
| Return on assets | 3.1% | 4.2% | 4.8% | 1.1% | 1.7% | |
| Operating ROA | 6.1% | 6.0% | 6.0% | 3.1% | 3.6% | |
| Return on tangible assets | 8.4% | 11.6% | 13.1% | 3.1% | 4.5% | |
| Return on equity | 5.6% | 7.2% | 8.2% | 1.9% | 3.2% | |
| Return on invested capital | 5.5% | 5.7% | 6.3% | 2.6% | 3.6% | |
| Return on capital employed | 6.6% | 6.8% | 6.9% | 3.7% | 4.3% | |
| Earnings yield | 4.0% | 4.2% | 4.0% | 0.9% | 1.6% | |
| Free cash flow yield | 8.3% | 5.3% | 4.7% | 4.0% | 5.2% | |
| Capex / Op. cash flow | 13.2% | 23.8% | 24.9% | 16.9% | 10.1% | |
| Capex / Depreciation | 20.5% | 35.8% | 41.5% | 23.5% | 16.2% | |
| Capex / Sales | 2.7% | 4.6% | 5.3% | 3.1% | 2.2% | |
| SG&A / Sales | 39.5% | 38.2% | 38.4% | 39.8% | 41.6% | |
| R&D / Sales | 5.6% | 5.7% | 6.2% | 5.9% | 6.4% | |
| Stock comp / Sales | 1.1% | 1.3% | 1.3% | 1.5% | 1.1% | |
| Intangibles / Total assets | 63.5% | 63.4% | 63.6% | 64.8% | 61.6% | |
| Days sales outstanding | 76d | 70d | 71d | 73d | 67d | |
| Days payables outstanding | 35d | 32d | 72d | 64d | 57d | |
| Operating cycle | 340d | 443d | 489d | 461d | 467d | |
| Cash conversion cycle | 305d | 410d | 417d | 397d | 410d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-17.0%EV / Sales ▼-15.0%EV / EBITDA ▼-7.5%EV / Op. cash flow ▼-3.523Earnings yield ▼-0.003Graham number ▼-6.713
Profitability
Return on equity ▼-0.017Return on assets ▼-0.012Return on invested capital ▼-0.002Return on capital employed ▼-0.002Operating ROA ▲+0.001Income quality ▲+0.750Tax burden ▼-0.023
Efficiency
Days sales outstanding ▲+5.192Days payables outstanding ▲+2.587Operating cycle ▼-103.027Cash conversion cycle ▼-105.615Capex / Sales ▼-0.019R&D / Sales ▼-0.001
Balance-sheet strength
Current ratio ▲+0.076Net debt / EBITDA ▲+0.601Working capital ▲+315600000.000Invested capital ▲+1588800000.000Intangibles / Total assets ▲+0.001
Change over 5 years
Valuation
Market cap ▼-30.7%EV / Sales ▼-36.7%EV / EBITDA ▼-43.4%EV / Op. cash flow ▼-7.038Earnings yield ▲+0.024Graham number ▲+20.413
Profitability
Return on equity ▲+0.024Return on assets ▲+0.013Return on invested capital ▲+0.019Return on capital employed ▲+0.023Operating ROA ▲+0.025Income quality ▼-0.958Tax burden ▲+0.044
Efficiency
Days sales outstanding ▲+8.236Days payables outstanding ▼-22.063Operating cycle ▼-127.566Cash conversion cycle ▼-105.502Capex / Sales ▲+0.005R&D / Sales ▼-0.008
Balance-sheet strength
Current ratio ▲+0.573Net debt / EBITDA ▼-0.943Working capital ▲+1119100000.000Invested capital ▲+1701000000.000Intangibles / Total assets ▲+0.019
Employee count
Peer market caps
Recent news
- 2026-09-28 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend Zimmer Biomet Holdings, Inc. (NYSE: ZBH - Get Free Report) declared a quarterly dividend on Friday, August 28th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share by the medical equipment provider on Friday, October 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The
- 2026-09-24 Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp State Street Corp boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 0.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,877,171 shares of the medical equipment provider''s stock after acquiring an additional 52,044 shares during
- 2026-09-17 Here''s Why Zimmer Biomet (ZBH) is a Strong Value Stock Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-09-10 Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV) Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Profitability This table compares Zimmer Biomet and CapsoVision''s net
- 2026-09-08 Is Zimmer Biomet Holdings Inc (ZBH) a Bargain After 3.9% Drop? GF Value Says Undervalued On September 08, 2026, Zimmer Biomet Holdings Inc (ZBH) shares fell 3.9% to a current price of $94.22. This decline comes amid a 52-week price range of $79.12 t
- 2026-09-08 Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
- 2026-09-04 Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report? Zimmer (ZBH) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-04 25,021 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Jupiter Topco LLC Jupiter Topco LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 25,021 shares of the medical equipment provider''s stock, valued at approximately $2,156,000. Other institutional investors and hedge funds have
- 2026-09-01 Zimmer Biomet - Showing Signs Of Life Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
- 2026-08-31 Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.